Tredu. Expert Education. Smarter Trading.

Mastering Equity and Stock Trading, Cryptocurrency Investment, Digital Assets and Global Forex Market Analysis: The Ultimate Masterclass at Tredu

Gain access to expert-led courses, live market analysis, and educational webinars that turn complex concepts into actionable strategies.Learn how to trade smarter and join our community of successful traders, building sustained financial growth.

Financial News

Maintain market dominance with real-time updates and expert analysis.
Our educators provide focused coverage across stock trading, forex markets, and crypto investing. We translate the latest financial news into practical knowledge, empowering you to trade smarter and achieve superior execution.

Proprietary Trading Strategies and
Quantitative Analysis

Sharpen your execution skills and gain a decisive edge with in-depth insights delivered by our top trading educators. Explore proven trading strategies, anticipate current market trends, and leverage expert analysis specifically designed to support your trading education and accelerate your path to sustained market success.

Tredu Team | Insights

Goldman Sachs Initiates CVR Energy With Sell Rating On Cash Flow Concerns

Goldman Sachs Initiates CVR Energy With Sell Rating On Cash Flow Concerns

Goldman Sachs initiated coverage on CVR Energy (NYSE: CVI) with a Sell rating and a $30.00 price target, citing concerns around capital allocation and potential downside risks to cash flow. The firm stated that its cautious stance was driven by expectations that the company would prioritize debt reduction and potential inorganic growth opportunities, which could delay any reinstatement of dividends into a longer-term event. While Goldman acknowledged a constructive outlook on the company’s small refinery exemption (SRE) potential at its Wynnewood facility, it also highlighted downside risks if such exemptions fail to materialize, noting that the company does not currently meet full compliance requirements. The firm estimated approximately 8% downside to current share levels, compared to its broader coverage universe, where it sees an average total return potential of around 15%.

Tredu Team | Insights

AbbVie Price Target Raised By Guggenheim Ahead Of Earnings

AbbVie Price Target Raised By Guggenheim Ahead Of Earnings

Guggenheim raised its price target on AbbVie (NYSE: ABBV) to $249 from $242, while maintaining a Buy rating, following updates to its financial model ahead of the company’s first-quarter 2026 earnings release scheduled for April 29. The firm adjusted its quarterly projections based on updated IQVIA prescription data and recent discussions with AbbVie’s investor relations team, expecting results to come in largely in line with company guidance. Guggenheim forecast first-quarter revenue of $14.65 billion and earnings per share of $2.57, compared to consensus estimates of $14.72 billion and $2.92. The discrepancy in EPS was attributed to the Street not fully reflecting a previously announced $0.41 dilution related to an in-process R&D charge, which lowered guidance to a range of $2.56 to $2.60. The firm also revised its medium-term outlook, increasing growth expectations for the immunology portfolio, particularly Skyrizi and Rinvoq, while trimming projections for the aesthetics segment, including Botox and Juvederm, based on recent trends. These revisions led to higher sales and earnings estimates for the 2028–2032 period, supporting the increased price target. Despite shares declining approximately 8% year-to-date compared to a modest decline in the S&P 500, Guggenheim maintained confidence that AbbVie would deliver high single-digit revenue growth through the remainder of the decade, supported by its existing portfolio and potential pipeline or business development opportunities.

Tredu Team | Insights

Goldman Sachs Upgrades Delek US To Buy On Free Cash Flow Outlook

Goldman Sachs Upgrades Delek US To Buy On Free Cash Flow Outlook

Goldman Sachs upgraded Delek US (NYSE: DK) to Buy from Neutral, assigning a $55.00 price target, based on expectations for improved free cash flow generation. The firm’s more positive outlook was supported by several factors, including internal cost-reduction initiatives, anticipated benefits from small refinery exemptions, enhancements in marketing and wholesale strategies, and stable growth in the company’s logistics segment. Goldman estimated that Delek could generate approximately $180 million in free cash flow in 2026, assuming partial SRE credits are realized. The firm indicated that this improved cash generation could support additional share repurchases and ongoing internal investment initiatives, ultimately strengthening long-term cash flow prospects.

Connect with Verified Trading
Educators for Tailored Mentorship
Across All Trading Styles

ADVANCED SEARCH

108 results

Top Brokers

Secure Your Trading Journey with the Right Broker

Advertisement for tredu.com - trading platform

Proud Media Partners of

Cyprus Fintech SummitMoney ExpoGlobal AI Show Abu DhabiGlobal Games ShowForex Expo DubaiGlobal Blockchain ShowEuropean Blockchain ConventionCyprus Fintech SummitMoney ExpoGlobal Games ShowFinancial Innovation ForumGlobal AI Show Abu DhabiForex Expo DubaiGlobal Games ShowCyprus Fintech SummitMoney ExpoGlobal Blockchain ShowEuropean Blockchain ConventionGlobal AI Show Abu DhabiFinancial Innovation ForumForex Expo DubaiGlobal Blockchain ShowCyprus Fintech SummitMoney ExpoEuropean Blockchain ConventionGlobal AI Show Abu DhabiFinancial Innovation ForumCyprus Fintech SummitMoney ExpoGlobal AI Show Abu DhabiGlobal Games ShowForex Expo DubaiGlobal Blockchain ShowEuropean Blockchain ConventionCyprus Fintech SummitMoney ExpoGlobal Games ShowFinancial Innovation ForumGlobal AI Show Abu DhabiForex Expo DubaiGlobal Games ShowCyprus Fintech SummitMoney ExpoGlobal Blockchain ShowEuropean Blockchain ConventionGlobal AI Show Abu DhabiFinancial Innovation ForumForex Expo DubaiGlobal Blockchain ShowCyprus Fintech SummitMoney ExpoEuropean Blockchain ConventionGlobal AI Show Abu DhabiFinancial Innovation Forum